Skip to main content
. 2022 Jan 11;2022(1):CD010037. doi: 10.1002/14651858.CD010037.pub4

Entezari 2015.

Study characteristics
Methods Double‐blinded placebo‐controlled clinical trial
Participants Normotensive females
Age: 18 to 30 years
Setting: Shahid Beheshti University of Medical Sciences in Tehran, Iran
Interventions Intervention: four capsules of supplementary calcium daily; each capsule contained 625 mg calcium carbonate, which is equal to 250 mg of calcium element.
Control: 1000 mg dextrose capsules instead of calcium carbonate
Trial duration: 1 month
Outcomes Systolic and diastolic blood pressure in supine position after 10 min of rest
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Not mentioned: "Eligible cases were randomly divided into two groups (treatment and control); treatment group received four capsules of supplementary calcium daily".
Allocation concealment (selection bias) Unclear risk The method was not described
Blinding of participants and personnel (performance bias)
All outcomes Unclear risk This double‐blinded placebo‐controlled clinical trial was carried out in normotensive females.
Blinding of outcome assessment (detection bias)
All outcomes Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes High risk 75 started; the authors did not mention how many in each group. More than "15 withdrew"; 22 in total (29.3%) finished "27 in calcium and 26 in control".
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk This study was done in a population who were calcium deficient, and therefore the effect of calcium supplement should be shown more prominently.